PTHS on NYSE
Pelthos Therapeutics Inc.
American biological products company based in Durham, incorporated in Nevada.
Price unavailable
Last updated Oct 18, 2026.
Overview
Compare with Mesoblast, Relay Therapeutics or Cullinan Oncology, or pick any stock.
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
What sells
Revenue by product, business segment and region, as the company reports it to the SEC.
Business segments
Commercial Operations brought in 96% of the revenue Pelthos Therapeutics Inc. broke down this way in fiscal 2025.
Business segments by year
| Business segments | 2024 | 2025 |
|---|---|---|
| Commercial Operations | $0 | $16.2M |
| Research And Development Operations | $0 | $589.0K |
Where the money goes
Where each dollar of revenue went, fiscal 2025
- Cost of revenue7¢$4.0M
- Research and development2¢$1.2M
- Selling, general and admin77¢$42.5M
- Income tax13¢$7.4M
Out of $16.8M in revenue.3 The company lost money this year.
Financial statements
Every line of the income statement as filed: the last 2 fiscal years, latest first.3
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Total revenue | $16.8M | $0 |
| Cost of goods sold | $4.0M | $0 |
| Selling, general and administrative | $42.5M | $6.4M |
| Research and development | $1.2M | $1.2M |
| Amortization of intangible assets | $1.6M | $0 |
| Total operating expenses | $49.2M | $7.6M |
| Operating loss | -$32.4M | -$7.6M |
| Interest expense | -$3.0M | -$786.0K |
| Impairment of intangible assets | -$285.0K | $0 |
| Change in fair value of convertible debt | -$15.0M | $0 |
| Interest income and other income | $5.0K | $402.0K |
| Total other (expense) income | -$18.3M | -$384.0K |
| Net loss before provision for income taxes | -$50.7M | -$8.0M |
| Provision for income taxes | -$7.4M | $0 |
| Net loss | -$43.3M | -$8.0M |
| Comprehensive loss | -$43.3M | -$8.0M |
| Net loss per common share, basic (in dollars per share) | -$23.04 | -$14.27 |
| Net loss per common share, diluted (in dollars per share) | -$23.04 | -$14.27 |
| Weighted average number of common shares outstanding, basic (in shares) | 1.9M shares | 557.4K shares |
| Weighted average number of common shares outstanding, diluted (in shares) | 1.9M shares | 557.4K shares |
No quarter-by-quarter statement was filed.
Every line of the balance sheet as filed: the last 3 fiscal years (annual) or 3 quarters (quarterly), latest first.3
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Cash and cash equivalents | $18.0M | $513.0K | |
| Restricted cash, current | $50.0K | $0 | |
| Accounts receivable, net | $8.9M | $0 | |
| Inventory, net | $23.6M | $0 | |
| Prepaid expenses and other current assets | $3.0M | $856.0K | |
| Total current assets | $53.4M | $1.4M | |
| Property and equipment, net | $9.6M | $0 | |
| Operating lease right-of-use assets, net | $3.2M | $0 | |
| Intangible assets, net | $39.5M | $0 | |
| Goodwill | $24.7M | $0 | |
| Total assets | $130.4M | $1.4M | |
| Accounts payable | $3.0M | $1.9M | |
| Accrued expenses | $15.4M | $0 | |
| Contingent consideration | $2.2M | $0 | |
| Operating lease liabilities, current portion | $635.0K | $0 | |
| Deferred revenue, current portion | $966.0K | $0 | |
| Other liabilities | $3.8M | $0 | |
| Total current liabilities | $26.0M | $4.1M | |
| Operating lease liabilities, net of current portion | $2.8M | $0 | |
| Deferred revenue, net of current portion | $1.3M | $0 | |
| Convertible debt | $31.4M | $0 | |
| Other long-term liabilities | $30.1M | $0 | |
| Total liabilities | $91.5M | $4.1M | |
| Common stock, value | $0 | $0 | |
| Additional paid in capital | $103.7M | $18.8M | |
| Accumulated deficit | -$64.8M | -$21.5M | |
| Total stockholders' equity (deficit) | $38.9M | -$2.7M | -$6.4M |
| Total liabilities and stockholders' equity (deficit) | $130.4M | $1.4M | |
| Common stock, par value (in dollars per share) | $0.00 | $0.00 | |
| Common stock, shares authorized (in shares) | 200.0M shares | 200.0M shares | |
| Common stock, shares, issued (in shares) | 3.2M shares | 610.4K shares | |
| Common stock, shares, outstanding (in shares) | 3.2M shares | 610.4K shares |
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Cash and cash equivalents | $18.0M | $513.0K | |
| Restricted cash, current | $50.0K | $0 | |
| Accounts receivable, net | $8.9M | $0 | |
| Inventory, net | $23.6M | $0 | |
| Prepaid expenses and other current assets | $3.0M | $856.0K | |
| Total current assets | $53.4M | $1.4M | |
| Property and equipment, net | $9.6M | $0 | |
| Operating lease right-of-use assets, net | $3.2M | $0 | |
| Intangible assets, net | $39.5M | $0 | |
| Goodwill | $24.7M | $0 | |
| Total assets | $130.4M | $1.4M | |
| Accounts payable | $3.0M | $1.9M | |
| Accrued expenses | $15.4M | $0 | |
| Contingent consideration | $2.2M | $0 | |
| Operating lease liabilities, current portion | $635.0K | $0 | |
| Deferred revenue, current portion | $966.0K | $0 | |
| Other liabilities | $3.8M | $0 | |
| Total current liabilities | $26.0M | $4.1M | |
| Operating lease liabilities, net of current portion | $2.8M | $0 | |
| Deferred revenue, net of current portion | $1.3M | $0 | |
| Convertible debt | $31.4M | $0 | |
| Other long-term liabilities | $30.1M | $0 | |
| Total liabilities | $91.5M | $4.1M | |
| Common stock, value | $0 | $0 | |
| Additional paid in capital | $103.7M | $18.8M | |
| Accumulated deficit | -$64.8M | -$21.5M | |
| Total stockholders' equity (deficit) | $38.9M | -$2.7M | -$6.4M |
| Total liabilities and stockholders' equity (deficit) | $130.4M | $1.4M | |
| Common stock, par value (in dollars per share) | $0.00 | $0.00 | |
| Common stock, shares authorized (in shares) | 200.0M shares | 200.0M shares | |
| Common stock, shares, issued (in shares) | 3.2M shares | 610.4K shares | |
| Common stock, shares, outstanding (in shares) | 3.2M shares | 610.4K shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow as filed: the last 2 fiscal years, latest first.3
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Net loss | -$43.3M | -$8.0M |
| Accretion of interest for royalty obligations | $2.4M | $0 |
| Change in fair value of convertible note | $15.0M | $0 |
| Depreciation of property and equipment | $729.0K | $0 |
| Amortization of intangible assets | $1.6M | $0 |
| Impairment of intangible assets | $285.0K | $0 |
| Amortization of debt discount | $259.0K | $692.0K |
| Lease amortization expense | $74.0K | $0 |
| Stock-based compensation | $5.5M | $1.8M |
| Inventory write-off | $1.1M | $0 |
| Gain on default judgment | $0 | -$363.0K |
| Accounts receivable | -$8.8M | $0 |
| Inventory | $1.8M | $0 |
| Prepaid expenses | -$880.0K | -$861.0K |
| Operating lease right-of-use assets | $345.0K | $0 |
| Accounts payable | $1.4M | $1.2M |
| Accrued expenses | $6.2M | -$283.0K |
| Contingent consideration | $2.2M | $0 |
| Operating lease liabilities | -$282.0K | $0 |
| Deferred revenue | -$589.0K | $0 |
| Deferred income tax | -$7.4M | $0 |
| Other assets and liabilities | $35.0K | $0 |
| Net cash used in operating activities | -$22.6M | -$5.8M |
| Purchases of property and equipment | -$99.0K | $0 |
| Acquisition of LNHC, Inc. | $2.8M | $0 |
| Net cash used in investing activities | -$5.2M | $0 |
| Proceeds from PIPE, net | $27.4M | $0 |
| Proceeds from stock option exercises | $206.0K | $0 |
| Proceeds from convertible note | $17.9M | $0 |
| Proceeds from loan payable, net of debt discount | $693.0K | $536.0K |
| Payment of loan payable, net of debt discount | -$845.0K | -$215.0K |
| Common stock issued for cash | $0 | $6.0M |
| Rescission of common stock | $0 | -$92.0K |
| Repurchase of common stock under stock repurchase plan | $0 | -$75.0K |
| Shares issued for cash under equity line of credit | $0 | $83.0K |
| Net cash provided by financing activities | $45.3M | $6.2M |
| Net increase in cash and cash equivalents | $17.5M | $417.0K |
| Cash paid for income taxes | $0 | $0 |
| Cash paid for interest expense | $19.0K | $0 |
| Royalty obligation extinguishment | $369.0K | $0 |
| Issuance costs allocated to convertible debt | $1.1M | $0 |
| PIPE proceeds allocated to accounts payable | $1.8M | $0 |
| PIPE proceeds allocated to debt payable | $20.3M | $0 |
| PIPE proceeds allocated to fees | $600.0K | $0 |
| Royalty agreement liability reclassified from additional paid in capital | $10.8M | $0 |
| Debt discount from common stock issued for extension of bridge loan | $0 | $448.0K |
| Shares issued for payment of accounts payable or for services | $53.0K | $7.0K |
| Conversion of notes to common stock | $737.0K | $1.4M |
| Transfer of liabilities to Chromocell Corporation for Series C Preferred Stock | $0 | $2.2M |
| Shares issued for payment of accrued interest | $0 | $3.0K |
| Shares issued for payment of principal on loan payable | $0 | $24.0K |
No quarter-by-quarter statement was filed.
Leadership
Who has led Pelthos Therapeutics Inc., and when. Pick a name to see everywhere that person has worked.
Chief executive
President
Chief financial officer
2025
- Chief executive officerScott M. Plesha Jul 23, 2025 to now8
- Chief executive officerKnuettel Francis Ii. Feb 15, 2024 to Jul 23, 20259
- PresidentScott M. Plesha Jul 23, 2025 to now8
- Chief financial officerJohn M. Gay Apr 20, 2026 to now10
- Chief financial officerKnuettel Francis Ii. Feb 15, 2024 to Apr 20, 20269
Board members and other officers (10)
- Chief Commercial OfficerSai Rangarao Jul 21, 2025 to now11
- Chief Medical OfficerEric Lang Feb 15, 2024 to Jun 18, 202412
- Board memberMatthew Pauls Jul 7, 2025 to now13
- Board memberPeter Greenleaf Jul 7, 2025 to now14
- Board memberRichard B. Baxter Jul 7, 2025 to now15
- Board memberScott M. Plesha Jul 23, 2025 to now8
- Board memberAndrew J. Einhorn Dec 29, 2025 to now16
- Board memberChia-Lin Simmons Feb 15, 2024 to now17
- Board memberEzra M. Friedberg Feb 15, 2024 to now18
- Board memberRichard Malamut Feb 15, 2024 to now19
Former names
Timeline
Filings
249 filings to the SEC since October 2021: 3 annual reports, 9 quarterly reports, 34 major events, 80 insider forms, 21 large holders, 4 private raises, 98 other. The latest 20:
- Oct 6, 20264 EDGAR
- Oct 6, 20264 EDGAR
- Oct 6, 20264 EDGAR
- Oct 1, 20268-K EDGAR
- Aug 18, 2026ARS EDGAR
- Aug 18, 2026DEFA14A EDGAR
- Aug 18, 2026DEF 14A EDGAR
- Aug 13, 202610-Q EDGAR
- Aug 13, 20268-K EDGAR
- Aug 13, 202610-Q/A EDGAR
- Aug 13, 20268-K EDGAR
- Aug 7, 2026PRE 14A EDGAR
- Jul 7, 20264 EDGAR
- Jul 7, 20264 EDGAR
- Jul 7, 20264 EDGAR
- Jun 17, 20264 EDGAR
- Jun 15, 20264 EDGAR
- May 28, 20268-K EDGAR
- May 26, 20264 EDGAR
- May 22, 2026144 EDGAR
The 249 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last three years, summarized. The full record is on SEC EDGAR.
Insider trades and holders
Large holders
Investors who own more than 5% must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively. 21 such filings since October 2021, the latest 10:
- May 15, 2026SCHEDULE 13G/A
- May 7, 2026SCHEDULE 13G/A
- Feb 17, 2026SCHEDULE 13G/A
- Feb 5, 2026SCHEDULE 13G/A
- Nov 14, 2025SCHEDULE 13G
- Nov 14, 2025SCHEDULE 13G/A
- Nov 10, 2025SCHEDULE 13D/A
- Aug 13, 2025SCHEDULE 13G/A
- Jul 8, 2025SCHEDULE 13G
- Jul 3, 2025SCHEDULE 13D/A
From Forms 4 and Schedules 13D and 13G filed with the SEC.
Money raised
Private offerings the company reported to the SEC on Form D.
- Nov 6, 2025Raised $18 million in a private offering of securities Form D: 8 investors so far Form D
- Jul 1, 2025Raised $50.1 million in a private offering of equity Form D: 13 investors so far Form D
- Aug 6, 2024Filed a private offering of equity Form D: $30 million offered in all Form D
- Jul 24, 2024Raised $750,000 in a private offering of debt Form D: 1 investor so far Form D
Held by these funds
The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026. Change is in shares since the quarter before.
13F reports cover disclosed long positions in U.S. stocks only.
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10SEC EDGARJohn M. Gay, Chief financial officer
- 11
- 12SEC EDGAREric Lang, Chief Medical Officer
- 13SEC EDGARMatthew Pauls, Board member
- 14SEC EDGARPeter Greenleaf, Board member
- 15SEC EDGARRichard B. Baxter, Board member
- 16SEC EDGARAndrew J. Einhorn, Board member
- 17SEC EDGARChia-Lin Simmons, Board member
- 18SEC EDGAREzra M. Friedberg, Board member
- 19SEC EDGARRichard Malamut, Board member